HL Financial Services LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 8.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,692 shares of the medical instruments supplier’s stock after buying an additional 512 shares during the period. HL Financial Services LLC’s holdings in Becton Dickinson and were worth $1,746,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Acropolis Investment Management LLC acquired a new position in Becton Dickinson and during the third quarter worth $101,000. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and during the second quarter worth $105,000. Truvestments Capital LLC acquired a new position in Becton Dickinson and during the third quarter worth $105,000. Bartlett & Co. LLC boosted its stake in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the last quarter. Finally, Bridgeworth LLC acquired a new position in Becton Dickinson and during the second quarter worth $131,000. 92.60% of the stock is currently owned by institutional investors.
In related news, EVP James C. Lim sold 5,189 shares of the stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the transaction, the executive vice president now owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.
Shares of Becton Dickinson and stock opened at $243.26 on Friday. Becton Dickinson and Co has a 52 week low of $209.91 and a 52 week high of $265.87. The firm has a market capitalization of $63.38 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.46 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the prior year, the company posted $2.40 EPS. The company’s quarterly revenue was up 39.0% on a year-over-year basis. Equities analysts forecast that Becton Dickinson and Co will post 12.2 earnings per share for the current fiscal year.
A number of equities analysts have weighed in on the company. Piper Jaffray Companies lowered their price objective on Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday. Barclays set a $260.00 price objective on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday. Wells Fargo & Co lowered their price objective on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday. KeyCorp boosted their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Citigroup boosted their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $254.07.
COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/11/10/hl-financial-services-llc-raises-position-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Read More: What is Cost of Debt?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.